| 2019-12-18 | Novartis Pharmaceuticals Corporation | $9,746 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | PROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF) | 2019 |
| 2019-11-26 | Mallinckrodt Enterprises LLC | $11,772 | Research payment | Cash or cash equivalent | OFIRMEV Drug, ACUTE CARE | RANDOMIZED CONTROL TRIAL OF INTRAVENOUS ACETAMINOPHEN OFIRMEV FOR THE REDUCTION OF INTRAPARTUM MATERNAL FEVER AND FETAL | 2019 |
| 2019-10-24 | Medtronic Vascular, Inc. | $250 | Charitable Contribution | Cash or cash equivalent | | | 2019 |
| 2019-10-09 | American Regent | $1,400 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
| 2019-07-08 | American Regent | $5,000 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
| 2019-06-25 | Medline Industries LP | $2,500 | Charitable Contribution | Cash or cash equivalent | | | 2019 |
| 2019-06-05 | Merck Sharp & Dohme LLC | $300 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NOXAFIL Drug, INFECTIOUS DISEASE | | 2019 |
| 2019-05-28 | CSL Behring | $9,000 | Research payment | Cash or cash equivalent | | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 |
| 2019-05-23 | Novartis Pharmaceuticals Corporation | $225 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP ACTIVE CONTROLLED 8 WEEK STUDY TO EVALUATE THE EFFECT OF LCZ696 VER | 2019 |
| 2019-05-22 | Merck Sharp & Dohme LLC | $300 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | EMEND Drug, ONCOLOGY | | 2019 |
| 2019-05-21 | Allergan, Inc. | $600 | Education | Cash or cash equivalent | | | 2019 |
| 2019-05-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2019 |
| 2019-05-08 | Gilead Sciences, Inc. | $300 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2019 |
| 2019-05-06 | PFIZER INC. | $600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | | 2019 |
| 2019-04-21 | AstraZeneca Pharmaceuticals LP | $300 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | | 2019 |
| 2019-04-19 | Janssen Pharmaceuticals, Inc | $300 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | | 2019 |
| 2019-04-10 | American Regent | $17,225 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
| 2019-04-10 | Amgen Inc. | $300 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Repatha Biological, Cardiology | | 2019 |
| 2019-04-02 | Mallinckrodt Enterprises LLC | $34,920 | Research payment | Cash or cash equivalent | OFIRMEV Drug, ACUTE CARE | RANDOMIZED CONTROL TRIAL OF INTRAVENOUS ACETAMINOPHEN OFIRMEV FOR THE REDUCTION OF INTRAPARTUM MATERNAL FEVER AND FETAL | 2019 |
| 2019-03-19 | AstraZeneca AB | $5,026 | Research payment | Cash or cash equivalent | FASENRA Drug, Respiratory | A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. | 2019 |
| 2019-01-21 | American Regent | $1,300 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
Comments